Labs / CDMO: development & manufacturing

Antag Therapeutics
Copenhagen, Denmark · antagtx.com
GLP
Antag Therapeutics develops first-in-class GIP receptor antagonist therapies for obesity, diabetes, and overweight. The company is based in Copenhagen, Denmark, and focuses on metabolic disease drug development and clinical-stage programs. It welcomes collaborators, investors, and scientific partners interested in its approach to obesity treatment.
They take quote requests by email.
What they offer
GIP receptor antagonism therapy development
Develops therapies based on GIP receptor antagonism for obesity and metabolic disease.
Clinical-stage drug development
Advances AT-7687 as a clinical-stage candidate and evaluates it in clinical studies.
Combination therapy development
Investigates AT-7687 both as monotherapy and in combination with other obesity therapies.
What they work on
- Modalities
- Peptide
- Species and models
- Non-human primate
- Therapeutic areas
- obesity, diabetes, overweight, metabolic disease, cardiometabolic disease
- Minimums and prices
- €80 million Series A financing
- Sites
- Copenhagen, Denmark
Similar labs. 3C Therapeutics, Alcami, Alphalyse, Arcinova
Found in a contract services directory. Listing built from antagtx.com. Work here? Claim this listing.